FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks

Food and Drug Administration scientists reviewing what could become the first medicine for the fatty liver disease NASH are skeptical the treatment’s safety risks outweigh its “modest” benefits, according to documents made public Wednesday.